FDA Releases COVID-19 Test Performance Data
IVDs from PerkinElmer and Viracor Eurofins were the most sensitive, agency says
The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.
You may also be interested in...
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
The US agency on 29 May gave two additional tools to COVID-19 test developers: an emergency use authorization template for tests using at-home sample collection kits, and a reference panel for the disease.
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.